Latest news with #LyellImmunopharma
Business Insider
a day ago
- Business
- Business Insider
Upcoming Stock Splits This Week (June 2 to June 6)
These are the upcoming stock splits for the week of June 2 to June 6, based on TipRanks' Stock Splits Calendar. A stock split is corporate move that increases the number of outstanding shares by distributing additional shares to existing shareholders, all without affecting the company's total market value. This typically results in a lower share price, making the stock more accessible, and potentially more attractive, to retail investors. Confident Investing Starts Here: While traditional stock splits aim to broaden appeal by lowering share prices, some companies take the opposite approach. A reverse stock split consolidates shares instead of dividing them, reducing the total count while raising the price per share. The overall market value remains unchanged, but the move is often used to comply with exchange listing requirements, such as Nasdaq's minimum price rule, and prevent delisting. Strategic actions like these, whether to draw in investors or stay listed, often offer signals that savvy traders pay attention to. Let's take a look at the upcoming stock splits for the week. ARB IOT Group (ARBB) – Singapore-based ARB IOT Group provides integrated Internet of Things (IoT) solutions, including smart buildings, industrial automation, and connected agriculture systems. On May 29, the company announced a 1-for-15 reverse stock split as part of its efforts to meet Nasdaq's minimum bid price requirement. The split is set to take effect on June 2. Lyell Immunopharma (LYEL) – Lyell Immunopharma is a clinical-stage biotech company developing T-cell reprogramming therapies for solid tumors. On May 29, the company announced a 1-for-20 reverse stock split as part of its effort to stay in line with Nasdaq's listing requirements. The split takes effect on June 2. Applied DNA Sciences (APDN) – Applied DNA Sciences develops and commercializes DNA-based technologies for therapeutic manufacturing, diagnostics, and supply chain security. On May 29, the company announced a 1-for-15 reverse stock split as part of its efforts to meet Nasdaq's continued listing standards. The split is set to take effect on June 2. Mullen Automotive (MULN) – California-based Mullen Automotive, known for its electric vehicles and battery tech, announced a 1-for-100 reverse stock split on May 29 in a bid to maintain its Nasdaq listing. The split, set to take effect on June 2, is part of the company's effort to meet minimum share price requirements and stay in compliance. Ekso Bionics (EKSO) – Ekso Bionics develops wearable robotic exoskeletons to enhance mobility for people with physical limitations and for industrial use. On May 21, EKSO announced a 1-for-15 reverse stock split to restore compliance with Nasdaq's minimum price rule. The split will take effect on June 2. AGM Group Holdings (AGMH) – AGM Group provides financial technology solutions and manufactures cryptocurrency mining equipment. On May 29, the company announced a 1-for-50 reverse stock split to meet Nasdaq listing criteria. The split will be effective on June 3. ClearOne (CLRO) – ClearOne designs and sells audio-visual communications equipment including microphones, conferencing systems, and network media streaming solutions. On May 21, the company announced a 1-for-15 reverse stock split to regain Nasdaq compliance. The split will be effective on June 2, with trading on a split-adjusted basis starting June 3. Oragenics (OGEN) – Oragenics is a biotechnology company focused on developing novel antibiotics and other treatments for infectious diseases. On May 28, the company announced a 1-for-30 reverse stock split to meet NYSE American listing standards. The split will be effective on June 3.
Business Insider
3 days ago
- Business
- Business Insider
Lyell Immunopharma trading halted, news pending
19:50 EDT Lyell Immunopharma (LYEL) trading halted, news pending Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Washington Post
13-05-2025
- Business
- Washington Post
Lyell Immunopharma: Q1 Earnings Snapshot
SOUTH SAN FRANCISCO, Calif. — SOUTH SAN FRANCISCO, Calif. — Lyell Immunopharma Inc. (LYEL) on Tuesday reported a loss of $52.2 million in its first quarter. On a per-share basis, the South San Francisco, California-based company said it had a loss of 18 cents. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 19 cents per share.
Yahoo
28-03-2025
- Business
- Yahoo
Is Lyell Immunopharma, Inc. (LYEL) the Cheapest Stock Insiders Are Buying In March?
We recently published a list of . In this article, we are going to take a look at where Lyell Immunopharma, Inc. (NASDAQ:LYEL) stands against other cheapest stocks insiders are buying in March. After solid gains Monday, the broader market index and blue chip companies traded flat Tuesday, while the NASDAQ Composite rose 0.2%. Monday's enthusiasm came from hopes of looser U.S. tariffs. Investors mostly ignored the March consumer confidence data released on Tuesday, which showed a sharp decline in U.S. consumers' short-term outlook on income, business, and job conditions, reports CNBC. 'Sentiment continues to wane among investors, consumers and businesses as economic concerns and economic policy uncertainty takes its toll,' said Bret Kenwell, U.S. investment analyst at eToro. 'Until there's more certainty on the tariff and macro front, sentiment and confidence remain vulnerable.' As investors navigate daily market changes, uncertainty remains a persistent factor. Insider trading tends to attract attention during these periods, as purchases of company stock by executives may suggest optimism about the company's future. However, insider selling doesn't necessarily signal a lack of confidence—it could simply be for personal financial reasons or to diversify holdings. Many executives use pre-established plans, such as 10b5-1, to maintain transparency. While insider trading can provide useful insights, it's important to evaluate it alongside a company's financial stability, broader market trends, and industry dynamics. What are some of the cheapest stocks insiders have been buying this month so far? To find out, we used Insider Monkey's insider trading stock screener, focusing only on stocks where at least two insiders had purchased shares in March. From there, we ranked the 10 stocks with the lowest average price per share. Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). With each stock, we note the average price per share of these purchases and the stock's market capitalization. A scientist in a laboratory manipulating a microscope to study a sample of cells. Market Capitalization: $165.09 million Lyell Immunopharma is a clinical-stage cell therapy company focused on developing CAR T-cell therapies for hematologic malignancies and solid tumors. The company is advancing therapies using innovative approaches to improve T-cell resistance to exhaustion and enhance antitumor activity. Lyell is developing the IMPT-314 dual-targeting CAR T-cell product for aggressive relapsed/refractory lymphoma and has a preclinical solid tumors program. The company reported a net loss of $191.9 million for the fourth quarter and $343.0 million for the year ended December 31, 2024, compared to a net loss of $52.9 million for the fourth quarter and $234.6 million for the year in 2023. Research and development (R&D) expenses were $48.7 million and $171.6 million for the fourth quarter and full year of 2024, respectively, compared to $47.0 million and $182.9 million for the same periods in 2023. Cash, cash equivalents and marketable securities as of December 31, 2024 were $383.5 million compared to $562.7 million as of December 31, 2023. Lyell believes that its cash, cash equivalents and marketable securities balances will be sufficient to meet working capital and capital expenditure needs into 2027. In March, two insiders, including the CFO, purchased approximately $312,752 worth of Lyell Immunopharma shares at an average price of $0.59 per share. The stock now trades at $0.56 per share, having dropped 12.62% year-to-date and 70.87% over the past 12 months. StockAnalysis reports that two analysts have rated Lyell Immunopharma stock as 'Sell' with a price target of $1.0. The average price target suggests a 78.89% upside from the latest price. Overall, LYEL ranks 6th on our list of cheapest stocks insiders are buying in March. While we acknowledge the potential of LYEL our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LYEL but that trades at less than 5 times its earnings, check out our report about the . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
31-01-2025
- Business
- Yahoo
Lyell Immunopharma, Inc. (NASDAQ:LYEL) has caught the attention of institutional investors who hold a sizeable 46% stake
Given the large stake in the stock by institutions, Lyell Immunopharma's stock price might be vulnerable to their trading decisions 50% of the business is held by the top 8 shareholders Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company To get a sense of who is truly in control of Lyell Immunopharma, Inc. (NASDAQ:LYEL), it is important to understand the ownership structure of the business. We can see that institutions own the lion's share in the company with 46% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company. Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. As a result, a sizeable amount of institutional money invested in a firm is generally viewed as a positive attribute. Let's delve deeper into each type of owner of Lyell Immunopharma, beginning with the chart below. View our latest analysis for Lyell Immunopharma Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. We can see that Lyell Immunopharma does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Lyell Immunopharma's historic earnings and revenue below, but keep in mind there's always more to the story. Hedge funds don't have many shares in Lyell Immunopharma. Arch Venture Partners, L.P. is currently the largest shareholder, with 12% of shares outstanding. For context, the second largest shareholder holds about 10% of the shares outstanding, followed by an ownership of 6.9% by the third-largest shareholder. We also observed that the top 8 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. Quite a few analysts cover the stock, so you could look into forecast growth quite easily. While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. We can see that insiders own shares in Lyell Immunopharma, Inc.. It has a market capitalization of just US$169m, and insiders have US$5.2m worth of shares, in their own names. Some would say this shows alignment of interests between shareholders and the board, though we generally prefer to see bigger insider holdings. But it might be worth checking if those insiders have been selling. The general public, who are usually individual investors, hold a 28% stake in Lyell Immunopharma. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. Private equity firms hold a 12% stake in Lyell Immunopharma. This suggests they can be influential in key policy decisions. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public. We can see that public companies hold 10% of the Lyell Immunopharma shares on issue. It's hard to say for sure but this suggests they have entwined business interests. This might be a strategic stake, so it's worth watching this space for changes in ownership. It's always worth thinking about the different groups who own shares in a company. But to understand Lyell Immunopharma better, we need to consider many other factors. For example, we've discovered 5 warning signs for Lyell Immunopharma (2 shouldn't be ignored!) that you should be aware of before investing here. If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
